Pembrolizumab resistance management

Pembrolizumab is an immune checkpoint inhibitor used to treat a variety of cancers, including non-small cell lung cancer, melanoma, head and neck squamous cell carcinoma, etc. But sometimes patients may develop resistance to pembrolizumab. It should be noted that when dealing with pembrolizumab resistance, one should work closely with and consult with doctors to develop an individualized treatment plan based on the specific situation.

Doctors may combine pembrolizumab with other treatments or chemotherapy drugs to make the treatment more effective. For example, it can be considered to be used in combination with chemotherapy drugs, radiotherapy, targeted drugs, etc. to improve the overall effect of treatment. During treatment with pembrolizumab, the dosing interval of the drug can be adjusted to avoid the development of resistance. Sometimes reducing dosing frequency can reduce the risk of drug resistance. Or participate in relevant clinical trials to find new treatment strategies and drugs to deal with pembrolizumab resistance.

PembrolizumabThe original drug is already on the market in China. SpecificationsThe price per box of 100mg/4ml may be around RMB 15,000. This drug is a strictly controlled drug and has not yet been included in medical insurance. Pembrolizumab The price of the European version of the original drug 100mg/4ml per box may be around RMB 25,000, and the price of the Turkish version of 100mg/4ml per box may be around 10,000 RMB (the price may fluctuate due to the exchange rate). The ingredients of the original drugs at home and abroad are basically the same, and they are expensive. There are currently no generic versions of Pembrolizumab available overseas.